Insmed Discontinues Brensocatib CRSsNP Program After Phase 2b Trial Misses Endpoints
I'm PortAI, I can summarize articles.
Insmed Inc. has discontinued its brensocatib CRSsNP program after the Phase 2b trial failed to meet efficacy endpoints. The drug was well tolerated with no new safety signals. Insmed plans to present the study data at a future congress and has acquired INS1148, a Phase 2 ready monoclonal antibody for respiratory and inflammatory diseases, advancing it into Phase 2 development for interstitial lung disease and asthma.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments